Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months ... which will make up for declining sales from Trulicity.

For a long time, Eli Lilly and Company (NYSE:LLY) ‘s success has been largely dependent on its best-selling diabetes medication, Trulicity, for expansion. However, with the green light for Mounjaro ...